267 Results for "

Multi-target

" in MedChemExpress (MCE) Product Catalog:
Products (267)

267 Results for "Multi-target" in MCE Product Catalog:

8
8 Cited Publications
Cat. No.: HY-10339
CAS No.: 1000669-72-6
Purity:  99.91%
Research Areas:  

Cancer

KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABL T315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10517
CAS No.: 252916-29-3
Purity:  99.13%
Synonyms: SU6668; TSU-68
Target:  

PDGFR FGFR VEGFR Apoptosis

Research Areas:  

Cancer

Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10206
CAS No.: 850879-09-3
Purity:  99.40%
Synonyms: MP470; HPK 56
Research Areas:  

Cancer

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-50751
CAS No.: 796967-16-3
Synonyms: ABT-869; AL-39324
Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-12201
CAS No.: 934541-31-8
Purity:  99.84%
Target:  

Aurora Kinase

Research Areas:  

Cancer

TAK-901 is a multi-targeted aurora inhibitor with IC50s of 21 and 15 nM for aurora A and B, respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10372
CAS No.: 1092788-83-4
Purity:  99.51%
Target:  

mTOR PDGFR VEGFR Src Apoptosis

Research Areas:  

Cancer

PP121 is a multi-targeted kinase inhibitor with IC50s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, VEGFR2, Src, PDGFR, respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15749
CAS No.: 898280-07-4
Purity:  99.64%
Research Areas:  

Endocrinology Cancer

XL228 is a multi-targeted tyrosine kinase inhibitor with IC50s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10987A
CAS No.: 934353-76-1
Purity:  99.99%
Research Areas:  

Cancer

ENMD-2076 is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10987
CAS No.: 1453868-32-0
Purity:  99.41%
Research Areas:  

Cancer

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-10185
CAS No.: 867331-64-4
Purity:  98.96%
Target:  

Src VEGFR FGFR PDGFR

Research Areas:  

Inflammation/Immunology

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132166
CAS No.: 2590556-80-0
Purity:  99.47%
Synonyms: M4205; IDRX-42
Target:  

c-Kit PDGFR c-Fms FLT3 Src

Research Areas:  

Cancer

Velzatinib (M4205) is a multi-target inhibitor for PDGFRB, PDGFRA, CSF1R, c-Kit, FLT3, and LCK, with an IC50s of 2.6, 50, 5.5, 44, 141 and 141 nM, respectively. Velzatinib exhibits antitumor efficacy in xenograft mouse models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N6028
CAS No.: 59219-65-7
Darutoside is an orally effective diterpene compound with significant anti-inflammatory, analgesic, wound healing promotion, and immunomodulatory activities. Darutoside reduces edema and pain responses by inhibiting the expression of COX-2 and the migration of inflammatory cells. It regulates macrophage polarization towards the M2 type by inhibiting the NF-κB pathway, alleviating inflammation and promoting wound healing. Through multi-target regulation of metabolic networks, Darutoside significantly alleviates acute gouty arthritis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-163885
CAS No.: 1262287-23-9
SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0381
CAS No.: 19908-48-6
Synonyms: DL-​Maackiain
Maackiain (DL-Maackiain) is an orally active multi-target inhibitor with anti-tumor activity and neuroprotective effects. Maackiain activates the AMPK, NLRP3 and Nrf2/HO-1 pathways, and inhibits key targets such as NF-κB, mTOR, MAO-B, NFATc1 and PKCδ, thereby precisely regulating processes including apoptosis, autophagy and pyroptosis. Maackiain also effectively inhibits microglial activation, osteoclast formation, and proliferation and invasion of tumor cells, and protects dopaminergic neurons from damage. Maackiain is applicable to the research of various diseases such as Alzheimer's disease, osteoporosis, sepsis and dengue fever 。
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N1437
CAS No.: 6205-14-7
Hydroxycitric acid is an orally active, multi-target, multi-bioactive organic acid. activates Nrf2 and its downstream molecule GPX4, increases glutathione levels, and thereby inhibits ferroptosis. Hydroxycitric acid activates the Nrf2/Keap1 and ACLY/NF-κB signaling pathways, upregulates the activities of antioxidant enzymes such as superoxide dismutase, reduces MDA content, thereby alleviating oxidative stress and renal tubular epithelial cell apoptosis, and improves pulmonary vascular and right ventricular remodeling. Hydroxycitric acid activates both the AMPK and mTORC1/S6K pathways, triggers the unfolded protein response, arrests the cancer cell cycle, and induces DNA fragmentation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2124
CAS No.: 174972-79-3
Parishin B is a multi-target biological agent with anti-epileptic, anti-fascioliasis and anti-breast cancer lung metastasis activities . Parishin B regulates the gene/protein activities of ACLY, unc13c, γ-aminobutynergic system, pro-inflammatory system, antioxidant system, monoaminergic system, ferroptosis-related pathways, as well as GST, CatL, Trx and TRIB3 . Parishin B modulates energy-lipid metabolism, synaptic function, neurotransmitter balance, neuroinflammation, oxidative stress, parasite detoxification/invasion processes, as well as apoptosis, cell cycle, proliferation and metastasis of cancer cells [1][2][3]. Parishin B can be used for related research of epilepsy, fascioliasis and breast cancer lung metastasis [3].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2157
CAS No.: 13161-75-6
Synonyms: (+)-Pteryxin
Pteryxin ((+)-Pteryxin) is an orally active multi-target inhibitor that targets NF-κB, MAPK, NLRP3 inflammasome, and Nrf2/ARE pathways. Pteryxin is also a BChE inhibitor (IC50=12.96 μg/mL) with a low inhibitory efficiency on AChE. Pteryxin inhibits the Ca 2+-calcineurin-NFATc1 pathway by blocking NF-κB/MAPK signaling, inhibiting NLRP3 inflammasome activation, and reducing ROS generation, and activates Nrf2-mediated antioxidant enzyme expression. Pteryxin has anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin can be used in the study of inflammatory diseases, osteoporosis, diabetes, and Alzheimer's disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W338584
CAS No.: 232281-44-6
Tripotassium hydroxycitrate is an orally active, multi-target, multi-bioactive organic acid. Tripotassium hydroxycitrate activates Nrf2 and its downstream molecule GPX4, increases glutathione levels, and thereby inhibits ferroptosis. Tripotassium hydroxycitrate activates the Nrf2/Keap1 and ACLY/NF-κB signaling pathways, upregulates the activities of antioxidant enzymes such as superoxide dismutase, reduces MDA content, thereby alleviating oxidative stress and renal tubular epithelial cell apoptosis, and improves pulmonary vascular and right ventricular remodeling. Tripotassium hydroxycitrate activates both the AMPK and mTORC1/S6K pathways, triggers the unfolded protein response, arrests the cancer cell cycle, and induces DNA fragmentation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10501
CAS No.: 627908-92-3
Purity:  99.11%
Target:  

PDGFR VEGFR c-Kit

Research Areas:  

Cancer

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0791
CAS No.: 1345847-93-9
Synonyms: DCC-2701
Research Areas:  

Cancer

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.
loading...
    loading...